Literature DB >> 18030990

Profiling heparin-chemokine interactions using synthetic tools.

Jose L de Paz1, E Ashley Moseman, Christian Noti, Laura Polito, Ulrich H von Andrian, Peter H Seeberger.   

Abstract

Glycosaminoglycans (GAGs), such as heparin or heparan sulfate, are required for the in vivo function of chemokines. Chemokines play a crucial role in the recruitment of leukocyte subsets to sites of inflammation and lymphocytes trafficking. GAG-chemokine interactions mediate cell migration and determine which leukocyte subsets enter tissues. Identifying the exact GAC sequences that bind to particular chemokines is key to understand chemokine function at the molecular level and develop strategies to interfere with chemokine-mediated processes. Here, we characterize the heparin binding profiles of eight chemokines (CCL21, IL-8, CXCL12, CXCL13, CCL19, CCL25, CCL28, and CXCL16) by employing heparin microarrays containing a small library of synthetic heparin oligosaccharides. The chemokines differ significantly in their interactions with heparin oligosaccharides: While some chemokines, (e.g., CCL21) strongly bind to a hexasaccharide containing the GlcNSO3(6-OSO3)-IdoA(2-OSO3) repeating unit, CCL19 does not bind and CXCL12 binds only weakly. The carbohydrate microarray binding results were validated by surface plasmon resonance experiments. In vitro chemotaxis assays revealed that dendrimers coated with the fully sulfated heparin hexasaccharide inhibit lymphocyte migration toward CCL21. Migration toward CXCL12 or CCL19 was not affected. These in vitro homing assays indicate that multivalent synthetic heparin dendrimers inhibit the migration of lymphocytes toward certain chemokine gradients by blocking the formation of a chemokine concentration gradient on GAG endothelial chains. These findings are in agreement with preliminary in vivo measurements of circulating lymphocytes. The results presented here contribute to the understanding of GAG-chemokine interactions, a first step toward the design of novel drugs that modulate chemokine activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18030990      PMCID: PMC2716178          DOI: 10.1021/cb700159m

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  56 in total

1.  Heparan sulfate and inflammation.

Authors:  Christopher R Parish
Journal:  Nat Immunol       Date:  2005-09       Impact factor: 25.606

2.  Microarrays of synthetic heparin oligosaccharides.

Authors:  Jose L de Paz; Christian Noti; Peter H Seeberger
Journal:  J Am Chem Soc       Date:  2006-03-08       Impact factor: 15.419

3.  Miniaturization of microwave-assisted carbohydrate functionalization to create oligosaccharide microarrays.

Authors:  Matthias A Brun; Matthew D Disney; Peter H Seeberger
Journal:  Chembiochem       Date:  2006-03       Impact factor: 3.164

4.  Sulfation patterns of glycosaminoglycans encode molecular recognition and activity.

Authors:  Cristal I Gama; Sarah E Tully; Naoki Sotogaku; Peter M Clark; Manish Rawat; Nagarajan Vaidehi; William A Goddard; Akinori Nishi; Linda C Hsieh-Wilson
Journal:  Nat Chem Biol       Date:  2006-07-30       Impact factor: 15.040

5.  Preparation and use of microarrays containing synthetic heparin oligosaccharides for the rapid analysis of heparin-protein interactions.

Authors:  Christian Noti; Jose L de Paz; Laura Polito; Peter H Seeberger
Journal:  Chemistry       Date:  2006-11-24       Impact factor: 5.236

6.  Immobilization and clustering of structurally defined oligosaccharides for sugar chips: an improved method for surface plasmon resonance analysis of protein-carbohydrate interactions.

Authors:  Yasuo Suda; Akio Arano; Yasuhiro Fukui; Shuhei Koshida; Masahiro Wakao; Tomoaki Nishimura; Shoichi Kusumoto; Michael Sobel
Journal:  Bioconjug Chem       Date:  2006 Sep-Oct       Impact factor: 4.774

7.  Microarrays of heparin oligosaccharides obtained by nitrous acid depolymerization of isolated heparin.

Authors:  Jose L de Paz; Dorothe Spillmann; Peter H Seeberger
Journal:  Chem Commun (Camb)       Date:  2006-06-14       Impact factor: 6.222

8.  Chemokine-glycosaminoglycan binding: specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry.

Authors:  Yonghao Yu; Matthew D Sweeney; Ola M Saad; Susan E Crown; Andro R Hsu; Tracy M Handel; Julie A Leary
Journal:  J Biol Chem       Date:  2005-07-20       Impact factor: 5.157

9.  Detection of oligosaccharide ligands for hepatocyte growth factor/scatter factor (HGF/SF), keratinocyte growth factor (KGF/FGF-7), RANTES and heparin cofactor II by neoglycolipid microarrays of glycosaminoglycan-derived oligosaccharide fragments.

Authors:  Keiko Yamaguchi; Hirotoshi Tamaki; Shigeyuki Fukui
Journal:  Glycoconj J       Date:  2006-11       Impact factor: 3.009

10.  Fabrication of carbohydrate microarrays on gold surfaces: direct attachment of nonderivatized oligosaccharides to hydrazide-modified self-assembled monolayers.

Authors:  Zheng-liang Zhi; Andrew K Powell; Jeremy E Turnbull
Journal:  Anal Chem       Date:  2006-07-15       Impact factor: 6.986

View more
  68 in total

Review 1.  B cell follicles and antigen encounters of the third kind.

Authors:  Jason G Cyster
Journal:  Nat Immunol       Date:  2010-10-19       Impact factor: 25.606

2.  Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes.

Authors:  Xingfeng Bao; E Ashley Moseman; Hideo Saito; Bronislawa Petryniak; Bronislawa Petryanik; Aude Thiriot; Shingo Hatakeyama; Yuki Ito; Hiroto Kawashima; Yu Yamaguchi; John B Lowe; Ulrich H von Andrian; Minoru Fukuda
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

Review 3.  Dendritic cell interactions with lymphatic endothelium.

Authors:  Erica Russo; Maximilian Nitschké; Cornelia Halin
Journal:  Lymphat Res Biol       Date:  2013-09       Impact factor: 2.589

4.  Towards the assembly of heparin and heparan sulfate oligosaccharide libraries: efficient synthesis of uronic acid and disaccharide building blocks.

Authors:  Akihiro Saito; Masahiro Wakao; Hiroshi Deguchi; Aya Mawatari; Michael Sobel; Yasuo Suda
Journal:  Tetrahedron       Date:  2010-05-29       Impact factor: 2.457

5.  Chemokine cooperativity is caused by competitive glycosaminoglycan binding.

Authors:  Guido J R Zaman; Martine J Smit; Folkert Verkaar; Jody van Offenbeek; Miranda M C van der Lee; Lambertus H C J van Lith; Anne O Watts; Angelique L W M M Rops; David C Aguilar; Joshua J Ziarek; Johan van der Vlag; Tracy M Handel; Brian F Volkman; Amanda E I Proudfoot; Henry F Vischer
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

Review 6.  Taking the lymphatic route: dendritic cell migration to draining lymph nodes.

Authors:  Alvaro Teijeira; Erica Russo; Cornelia Halin
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

7.  Chemoenzymatic synthesis of unmodified heparin oligosaccharides: cleavage of p-nitrophenyl glucuronide by alkaline and Smith degradation.

Authors:  Xing Zhang; Yongmei Xu; Po-Hung Hsieh; Jian Liu; Lei Lin; Eric P Schmidt; Robert J Linhardt
Journal:  Org Biomol Chem       Date:  2017-02-01       Impact factor: 3.876

8.  Evidence of positive selection at codon sites localized in extracellular domains of mammalian CC motif chemokine receptor proteins.

Authors:  Kelsey J Metzger; Michael A Thomas
Journal:  BMC Evol Biol       Date:  2010-05-10       Impact factor: 3.260

Review 9.  Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature's longest or most complex carbohydrate chains.

Authors:  Paul L DeAngelis; Jian Liu; Robert J Linhardt
Journal:  Glycobiology       Date:  2013-03-11       Impact factor: 4.313

Review 10.  Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans.

Authors:  Tiziana Adage; Anna-Maria Piccinini; Angelika Falsone; Martin Trinker; James Robinson; Bernd Gesslbauer; Andreas J Kungl
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.